Suppr超能文献

肢端肥大症的多学科管理:共识。

Multidisciplinary management of acromegaly: A consensus.

机构信息

Institute of Endocrine and Metabolic Sciences, San Raffaele Vita-Salute University, IRCCS San Raffaele Hospital, Ospedale San Raffaele, Via Olgettina, 58, 20132, Milan, Italy.

Pacific Pituitary Disorders Center, Pacific Neuroscience Institute, Santa Monica, CA, USA.

出版信息

Rev Endocr Metab Disord. 2020 Dec;21(4):667-678. doi: 10.1007/s11154-020-09588-z. Epub 2020 Sep 10.

Abstract

The 13th Acromegaly Consensus Conference was held in November 2019 in Fort Lauderdale, Florida, and comprised acromegaly experts including endocrinologists and neurosurgeons who considered optimal approaches for multidisciplinary acromegaly management. Focused discussions reviewed techniques, results, and side effects of surgery, radiotherapy, and medical therapy, and how advances in technology and novel techniques have changed the way these modalities are used alone or in combination. Effects of treatment on patient outcomes were considered, along with strategies for optimizing and personalizing therapeutic approaches. Expert consensus recommendations emphasize how best to implement available treatment options as part of a multidisciplinary approach at Pituitary Tumor Centers of Excellence.

摘要

第 13 届肢端肥大症共识会议于 2019 年 11 月在美国佛罗里达州劳德代尔堡举行,会议召集了内分泌学家和神经外科医生等肢端肥大症专家,共同探讨了肢端肥大症的多学科管理的最佳方法。重点讨论了手术、放疗和药物治疗的技术、结果和副作用,以及技术进步和新技术如何改变了这些方法单独或联合使用的方式。还考虑了治疗对患者结局的影响,以及优化和个性化治疗方法的策略。专家共识建议强调了如何最好地将现有的治疗选择作为垂体肿瘤卓越中心多学科方法的一部分来实施。

相似文献

1
Multidisciplinary management of acromegaly: A consensus.
Rev Endocr Metab Disord. 2020 Dec;21(4):667-678. doi: 10.1007/s11154-020-09588-z. Epub 2020 Sep 10.
2
AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly.
Endocr Pract. 2004 May-Jun;10(3):213-25. doi: 10.4158/EP.10.3.213.
3
Multi-modal management of acromegaly: a value perspective.
Pituitary. 2015 Oct;18(5):658-65. doi: 10.1007/s11102-014-0626-1.
4
Modern treatment of acromegaly.
Postgrad Med J. 2003 Apr;79(930):189-93; quiz 192-4. doi: 10.1136/pmj.79.930.189.
5
Management of acromegaly: is there a role for primary medical therapy?
Rev Endocr Metab Disord. 2008 Mar;9(1):83-94. doi: 10.1007/s11154-007-9061-1.
6
[Therapeutic management of acromegaly].
Med Klin (Munich). 2006 Jan 15;101(1):15-23. doi: 10.1007/s00063-006-1004-1.
7
Diagnosis and treatment of acromegaly and its complications: consensus guidelines.
J Endocrinol Invest. 2005;28(11 Suppl International):43-7.
8
How effective are current therapies for acromegaly?
Growth Horm IGF Res. 2003 Aug;13 Suppl A:S144-51. doi: 10.1016/s1096-6374(03)00072-8.
9
Current therapy and drug pipeline for the treatment of patients with acromegaly.
Adv Ther. 2009 Apr;26(4):383-403. doi: 10.1007/s12325-009-0029-9. Epub 2009 May 4.
10
Current therapies and mortality in acromegaly.
J Med Life. 2015 Oct-Dec;8(4):411-5.

引用本文的文献

1
Adherence, duration and healthcare costs in a real-world population of patients with acromegaly.
J Comp Eff Res. 2025 Sep;14(9):e250080. doi: 10.57264/cer-2025-0080. Epub 2025 Jul 8.
2
Management of acromegaly beyond primary surgery: efficacy and safety of repeat surgery and radiotherapy.
Acta Neurochir (Wien). 2025 Aug 18;167(1):223. doi: 10.1007/s00701-025-06640-2.
4
Consensus on acromegaly therapeutic outcomes: an update.
Nat Rev Endocrinol. 2025 Aug 13. doi: 10.1038/s41574-025-01148-2.
6
Impact of Medical Therapies on Cardiovascular Risk Factors in Acromegaly.
Cureus. 2025 Jun 16;17(6):e86106. doi: 10.7759/cureus.86106. eCollection 2025 Jun.
8
Management of patients with acromegaly in clinical practice in the gulf countries: a Delphi consensus survey.
Front Endocrinol (Lausanne). 2025 Jun 12;16:1593959. doi: 10.3389/fendo.2025.1593959. eCollection 2025.
9
Pituitary incidentaloma: a Pituitary Society international consensus guideline statement.
Nat Rev Endocrinol. 2025 Jun 24. doi: 10.1038/s41574-025-01134-8.

本文引用的文献

1
Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide.
J Clin Endocrinol Metab. 2020 Oct 1;105(10):e3785-97. doi: 10.1210/clinem/dgaa526.
2
Pituitary Tumors Centers of Excellence.
Endocrinol Metab Clin North Am. 2020 Sep;49(3):553-564. doi: 10.1016/j.ecl.2020.05.010. Epub 2020 Jul 15.
6
Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly.
Eur J Endocrinol. 2020 Jun;182(6):D17-D29. doi: 10.1530/EJE-19-0998.
7
Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study.
Eur J Endocrinol. 2020 Jun;182(6):583. doi: 10.1530/EJE-19-0762.
8
Acromegaly and Vertebral Fractures: Facts and Questions.
Trends Endocrinol Metab. 2020 Apr;31(4):274-275. doi: 10.1016/j.tem.2020.01.011. Epub 2020 Feb 13.
9
Pituitary-Tumor Endocrinopathies.
N Engl J Med. 2020 Mar 5;382(10):937-950. doi: 10.1056/NEJMra1810772.
10
Random Gh and Igf-I levels after transsphenoidal surgery for acromegaly: relation with long-term remission.
Endocrine. 2020 Apr;68(1):182-191. doi: 10.1007/s12020-020-02227-2. Epub 2020 Feb 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验